ITM 2.0: Advancing Translational Science in Metropolitan Chicago

ITM 2.0：推进芝加哥大都市的转化科学

• 批准号: 10208473
• 负责人: Joshua J Jacobs
• 金额: $ 174.15万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-06 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10208473
• 关键词: Academic Medical Centers; Acute; Advocate; Anti-Inflammatory Agents; Award; Biotechnology; COVID-19; Case Series; Cessation of life; Chicago; Chronic; Clinical Research; Clinical Sciences; Collaborations; Communities; Consumption; Data; Diet; Disease; Dose; Eating; Effectiveness; Elderly; Ethics; Exposure to; Failure; Fishes; General Population; Goals; Health; Health Personnel; Healthcare; Home environment; Hospitalization; Hour; Human; Hypercalcemia; Illinois; Industry; Infection; Inflammatory; Infrastructure; Institute of Medicine (U.S.); Institutes; Institution; Intake; Intervention; Lead; Medicine; Meta-Analysis; Molecular Genetics; Monitor; Morbidity - disease rate; Negative Finding; Nursing Homes; Outcome; Patient Recruitments; Persons; Population; Pregnant Women; Prevention; Process; Public Health; Published Comment; Randomized; Recommended Daily Allowances; Relative Risks; Research; Research Subjects; Research Training; Resources; Respiratory Tract Infections; Risk; Science; Scientist; Skin; Social Justice; Source; Suggestion; Sun Exposure; Technology; Testing; Toxic effect; Training; Translational Research; Trust; Uncertainty; Universities; Ventilator; Viral Respiratory Tract Infection; Vision; Vitamin D; Vitamin D Deficiency; Vitamins; Work; base; bone; clinical practice; compare effectiveness; convict; coronavirus disease; design; disorder risk; dosage; effective intervention; experimental study; falls; high risk; immunoregulation; improved; improved outcome; innovation; interest; metropolitan; mortality; multidisciplinary; population health; precision medicine; preference; prevent; secondary analysis; seroconversion; side effect; social determinants; success; synergism; translational medicine; translational pipeline; willingness

ABSTRACT ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.

抽象的 ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrated, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiological, and social determiners of disease; to develop and test interventions directed towards those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, Respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translated research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through Collaborative, multidisciplinary team science. We will work towards this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value proposals to improve Mutually defined health concerns, leveraging synergies that accelerate progress across the translational 光谱。我们的核心信念是，参与卫生研究是共同的自身利益和 social justice, a “new normal” prevailing viewpoint towards which we will strive together over the next 20 years. ITM 2.0将与整个芝加哥和全国各地的健康利益相关者携手合作， Conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. 为这一雄心勃勃的挑战做准备，我们扩大了机构和社区利益相关者的范围。 Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate 医疗保健加入ITM分支机构。我们与受人尊敬的机构合作 - 芝加哥社区信托基金会， 伊利诺伊州生物技术行业组织以及芝加哥和伊利诺伊州公共卫生部门 - 包括与其他两个芝加哥CTSA的牢固合作，与芝加哥范围的PCORNET合作 CDRN摩ri座，以及最近被授予的伊利诺伊州精密医学财团。在ITM 2.0中，我们将 共同开发创新的，有时是破坏性的方法，以推进科学和实践 严格确定哪种方法工作，然后传播，临床和翻译研究 成功和失败的结果。我们希望这种方法将改善和 对芝加哥，CTSA财团和国家的临床和翻译研究培训。